Show simple item record

dc.contributor.authorSogkas, Georgios
dc.contributor.authorDubrowinskaja, Natalia
dc.contributor.authorBergmann, Anke K
dc.contributor.authorLentes, Jana
dc.contributor.authorRipperger, Tim
dc.contributor.authorFedchenko, Mykola
dc.contributor.authorErnst, Diana
dc.contributor.authorJablonka, Alexandra
dc.contributor.authorGeffers, Robert
dc.contributor.authorBaumann, Ulrich
dc.contributor.authorSchmidt, Reinhold E
dc.contributor.authorAtschekzei, Faranaz
dc.date.accessioned2019-06-12T09:47:46Z
dc.date.available2019-06-12T09:47:46Z
dc.date.issued2019-04-04
dc.identifier.citationDiseases. 2019 Apr 4;7(2). pii: diseases7020034. doi: 10.3390/diseases7020034en_US
dc.identifier.issn2079-9721
dc.identifier.pmid30987377
dc.identifier.doi10.3390/diseases7020034
dc.identifier.urihttp://hdl.handle.net/10033/621814
dc.description.abstractImmunodeficiency, centromeric instability and facial anomalies syndrome 2 (ICF2) is a rare autosomal recessive primary immunodeficiency disorder. So far, 27 patients have been reported. Here, we present three siblings with ICF2 due to a homozygous ZBTB24 gene mutation (c.1222 T>G, p. (Cys408Gly)). Immune deficiency in these patients ranged from late-onset combined immunodeficiency (CID) with severe respiratory tract infections and recurrent shingles to asymptomatic selective antibody deficiency. Evident clinical heterogeneity manifested despite a common genetic background, suggesting the pathogenic relevance of epigenetic modification. Immunological follow-up reveals a previously unidentified gradual depletion of B and CD4+ T cells in all three presented patients with transition of a common variable immunodeficiency (CVID)-like disease to late-onset-CID in one of them. Considering all previously published cases with ICF2, we identify inadequate antibody responses to vaccines and reduction in CD27+ memory B cells as prevalent immunological traits. High mortality among ICF2 patients (20%) together with the progressive course of immunodeficiency suggest that hematopoietic stem cell transplantation (HSCT) should be considered as a treatment option in due time.en_US
dc.language.isoenen_US
dc.publisherMPDIen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectB cell immunodeficiencyen_US
dc.subjectICF syndromeen_US
dc.subjectICF2en_US
dc.subjectT cell immunodeficiencyen_US
dc.subjectZBTB24en_US
dc.subjectcombined immunodeficiencyen_US
dc.titleProgressive Immunodeficiency with Gradual Depletion of B and CD4⁺ T Cells in Immunodeficiency, Centromeric Instability and Facial Anomalies Syndrome 2 (ICF2).en_US
dc.typeArticleen_US
dc.contributor.departmentHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.en_US
dc.identifier.journalDiseasesen_US
refterms.dateFOA2019-06-12T09:47:46Z
dc.source.journaltitleDiseases (Basel, Switzerland)


Files in this item

Thumbnail
Name:
Sogkas et al.pdf
Size:
1.359Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International